Education
About Us
Working with TipRanks
Follow Us
Peptidream Inc. (JP:4587)
:4587
Top Page
Peptidream
(OTC:4587)
Select Model
Select Model
Rating:52Neutral
Price Target:
¥1,732.00
▲(3.03% Upside)
Peptidream's overall stock score is primarily impacted by its mixed financial performance, with significant revenue decline and profitability challenges. Technical analysis shows short-term bullish momentum, but valuation concerns due to a negative P/E ratio weigh heavily on the score.
Peptidream (4587) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
$218.24B
Dividend YieldN/A
Average Volume (3M)1.07M
Price to Earnings (P/E)14.7
Beta (1Y)1.05
Revenue Growth-65.56%
EPS Growth-123.22%
CountryJP
Employees621
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-8.43
Shares Outstanding130,010,400
10 Day Avg. Volume1,295,550
30 Day Avg. Volume1,068,690
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.91
Enterprise Value/Revenue10.38
Enterprise Value/Gross Profit25.71
Enterprise Value/Ebitda-51.76
Forecast
1Y Price Target
$1,490.96Price Target Upside-11.31% Downside
Rating ConsensusHold
Number of Analyst Covering0
Peptidream Business Overview & Revenue Model
Company DescriptionPeptiDream Inc., a biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics. The company develops its products based on its Peptide Discovery Platform System, a drug finding platform for the development of peptides. It has a collaborative research and exclusive license agreement with Takeda Pharmaceutical Company Limited to develop peptide drug conjugates for neuromuscular diseases. The company was incorporated in 2006 and is headquartered in Kawasaki, Japan.
How the Company Makes MoneyPeptiDream generates revenue primarily through strategic partnerships and collaborations with leading pharmaceutical companies. These partnerships often involve upfront payments, milestone payments, and royalties on sales of successfully developed therapeutics. The company also licenses its proprietary technology and platform to other firms, providing another stream of income. Additionally, PeptiDream may engage in joint research and development projects, wherein costs and profits are shared with partners, further contributing to its revenue. Significant partnerships with major pharmaceutical companies enhance its financial performance and bolster its market presence.
Peptidream Earnings Call Summary
Earnings Call Date:Aug 07, 2025
(Q2-2024)
| % Change Since: |
Next Earnings Date:Nov 06, 2025
Earnings Call Sentiment Positive
The earnings call presented a largely positive outlook for the company with strong financial performance and promising pipeline developments, despite some challenges in specific segments and uncertainties in deal closures.Q2-2024 Updates
Positive Updates
Strong First Half Financial Performance
Revenue of JPY 36 billion, which exceeded the initial forecast. Core operating profit reached JPY 24 billion and net income was JPY 18 billion.
Successful Novartis Collaboration and Expansion
The Novartis collaboration expanded and contributed significantly to revenues. Multiple programs are progressing towards clinical entry, with a new component of peptide drug conjugate programs added.
Positive Currency Exchange and Cash Position
Achieved a favorable currency exchange rate with USD 157-158 per JPY and holding over JPY 50 billion in cash as of the end of July.
Promising Pipeline Developments
Progress in the radiopharmaceutical pipeline with several programs moving towards clinical stages. Notable progress in non-radiopharmaceuticals including macrocyclic peptides and oral peptide therapeutics.
Strategic Partnerships and New Management
Strategic partnerships like the acquisition of Amolyt Pharma by AstraZeneca enhance program development. New management in PDRadiopharma to drive growth.
Negative Updates
Challenges in SPECT Business
Continued slow recovery and weakness in the SPECT business segment, impacting revenue growth potential.
Currency Risk and Deal Finalization Delays
Exposure to currency risks due to deal finalization delays and USD to JPY conversion.
Uncertainty in Deal Closures
Some collaboration and out-licensing deals may be delayed to 2025, causing uncertainty in revenue projections.
Company Guidance
During the Q2 2024 earnings call for PeptiDream (4587.T), executive Patrick Reed provided detailed guidance for the second half of 2024 and touched upon early 2025 projections. The company reported a first-half revenue of approximately JPY 36 billion, with JPY 28.5 billion from PeptiDream and JPY 7.6 billion from its radiopharmaceutical business, PDRadiopharma. This surpasses their initial annual revenue forecast of JPY 35 billion, revised to JPY 45 billion following a collaboration with Novartis. Core operating profit and net income exceeded 100% of their goals, reaching JPY 24 billion and JPY 18 billion, respectively. Reed highlighted potential for upward revisions in earnings, driven by additional revenue sources and ongoing negotiations with pharmaceutical partners. The company forecasts second-half milestones and R&D funding between JPY 1.2 billion and JPY 2.5 billion, and anticipates total revenue for fiscal 2024 to be between JPY 15.4 billion and JPY 16.2 billion for PDRadiopharma. The call also emphasized strategic expansions, such as the Novartis collaboration and potential new partnerships, aiming to sustain the company's financial momentum into 2025.Peptidream Financial Statement Overview
Summary
Peptidream demonstrates strong financial health with consistent revenue growth, improving net profit margins, strong EBIT and EBITDA margins, a solid equity position, and robust cash flow generation. There is a moderate leverage risk that should be managed carefully.Income Statement
Peptidream shows robust performance with consistent revenue growth, improving net profit margin, and strong EBIT and EBITDA margins. The company has experienced significant revenue growth, particularly in recent years, which is a positive indicator for future profitability.45
Neutral
Balance Sheet
The balance sheet reflects a strong equity position with a healthy equity ratio, though the debt-to-equity ratio is moderate, indicating some leverage risk. Return on equity is commendable, reflecting efficient use of equity to generate profits.65
Positive
Cash Flow
Peptidream's cash flow is strong, with a significant operating cash flow to net income ratio and positive free cash flow. The company has shown resilience in generating cash from operations, although past fluctuations in free cash flow growth rate suggest potential volatility.50
Neutral
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 19.09B | 46.68B | 28.71B | 26.85B | 9.42B | 11.68B |
| Gross Profit | 7.71B | 34.50B | 17.22B | 18.11B | 7.01B | 9.53B |
| EBITDA | -3.83B | 23.36B | 7.38B | 9.02B | 5.01B | 7.56B |
| Net Income | -5.03B | 15.01B | 3.04B | 7.55B | 2.57B | 4.45B |
Balance Sheet | ||||||
| Total Assets | 78.54B | 92.77B | 69.46B | 63.87B | 26.62B | 26.27B |
| Cash, Cash Equivalents and Short-Term Investments | 33.33B | 48.12B | 19.51B | 5.25B | 11.75B | 7.15B |
| Total Debt | 18.98B | 19.63B | 22.80B | 21.68B | 0.00 | 0.00 |
| Total Liabilities | 24.86B | 36.01B | 29.11B | 31.82B | 1.62B | 5.05B |
| Stockholders Equity | 53.67B | 56.76B | 40.35B | 32.04B | 25.35B | 21.22B |
Cash Flow | ||||||
| Free Cash Flow | 13.49B | 21.77B | 11.05B | -4.06B | 5.44B | 1.15B |
| Operating Cash Flow | 15.55B | 23.84B | 12.42B | -82.93M | 6.65B | 1.73B |
| Investing Cash Flow | -2.87B | 8.37B | 1.30B | -27.38B | -2.28B | -1.20B |
| Financing Cash Flow | -3.99B | -2.99B | 264.19M | 20.79B | 66.07M | -237.24M |
Peptidream Technical Analysis
Positive
1681.00
Price Trends
1616.28
Positive
1677.72
Positive
1974.76
Negative
Market Momentum
29.29
Negative
55.81
Neutral
69.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4587, the sentiment is Positive. The current price of 1681 is above the 20-day moving average (MA) of 1594.05, above the 50-day MA of 1616.28, and below the 200-day MA of 1974.76, indicating a neutral trend. The MACD of 29.29 indicates Negative momentum. The RSI at 55.81 is Neutral, neither overbought nor oversold. The STOCH value of 69.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4587.
Peptidream Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | 115.84B | 199.72 | 0.53% | 1.77% | 6.98% | 406.15% | |
52 Neutral | $218.24B | 14.74 | -9.08% | ― | -65.56% | -123.22% | |
49 Neutral | 89.95B | -27.36 | -4.97% | ― | 33.71% | 68.32% | |
48 Neutral | 173.80B | -47.69 | 0.00% | ― | 0.00% | -58.12% | |
46 Neutral | 67.40B | -9.54 | -476.97% | ― | -78.54% | 10.23% | |
42 Neutral | 138.85B | -878.23 | -0.76% | ― | 2.04% | -102.04% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
JP:4587
Peptidream
1,681.00
-855.00
-33.71%
DE:3G6
GNI Group
14.10
-3.30
-18.97%
SNBIF
SanBio Co
16.45
12.60
327.27%
SOLTF
Sosei Group
7.04
-2.22
-23.97%
JP:4593
Healios KK
584.00
325.00
125.48%
JP:4974
Takara Bio Inc.
962.00
-40.94
-4.08%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.